Plain-English translation of NCT06215950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach called CD70-targeted CAR-T therapy, which uses your own immune cells that have been genetically engineered in a laboratory to recognize and attack cancer cells. The treatment is being tested in two ways: as an infusion into your bloodstream or as an injection into your abdominal cavity. Researchers want to find the safest and most effective dose of this medication.
Women with advanced gynecologic cancers often run out of treatment options when standard therapies (surgery, chemotherapy, radiation) stop working or cause unbearable side effects. This medication represents a new strategy — using your body's own immune system to fight back — and researchers hope it will help patients who have no other options.
You likely qualify if…
You likely don't qualify if…
The study has two phases. First, researchers will test different doses of the engineered immune cells in small groups to find the safest dose. Then, they will treat more patients at that dose to confirm it works. You will receive the medication either as an infusion into your vein or as an injection into your abdomen. Throughout the trial, you will have blood tests, imaging scans, and regular clinic visits so doctors can monitor how you respond and watch for any side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China